About this archived opportunity

February 23, 2026 ADVOCATE ISO, ARPA-H-SOL-26-142, Amendment 02: The purpose of ARPA-H-SOL-26-142, Amendment 02 is to revise the following sections as shown in the highlighted text: Table of Contents TA1: CVD Agent � Reliable Agentic Care Management under Section 1.2.1 Technical Areas (TA) Phase 2 (15 months) � Scalability Studies under Section 1.2.2 Program Structure & Timeline Section 3. Submission Information Section 4.1 Solution Summary Review Process Section 4.2 Full Proposal Evaluation Criteria Section 4.2.1 Criteria 1: Overall Scientific and Technical Merit Section 4.4 Handling of Sensitive Information See attached ADVOCATE ISO, ARPA-H-SOL-26-142, Amendment 02. __________________________ February 5, 2026 ADVOCATE ISO, ARPA-H-SOL-26-142, Amendment 01: The purpose of ARPA-H-SOL-26-142, Amendment 01 is as follows: Make a correction to Table 7 � Performer Collaboration Expectations under Section 1.2.5 Performer Collaboration Expectations (See highlighted text). Revise the last paragraph under Section 5.1 Proposing Teams (See highlighted text) to read: �Proposers interested in submitting a proposal for TA3 cannot submit a proposal for TA1 and TA2 in any capacity (e.g. prime, subperformer, or multi-party team). TA3 proposers can only submit one proposal for the TA3 work outlined in this solicitation.� Update the first sentence of Section 6.2 Conflicts of Interest (OCI) (See highlighted text) to read: �The proposer, through submission of a proposal, is required to identify and disclose all facts relevant to any potential OCI involving the proposer, its , and/or any proposed team member (i.e. proposed sub-performer, consultant).� See attached ADVOCATE ISO, ARPA-H-SOL-26-142, Amendment 01. ___________________ January 13, 2026 The Advanced Research Projects Agency for Health (ARPA-H) Agentic AI-Enabled Cardiovascular Care Transformation (ADVOCATE) program will enable the development of an Agentic system that delivers autonomous and semi-autonomous clinical care directly to patients with cardiovascular disease (CVD). Interested parties are invited to review the attached ADVOCATE Innovative Solutions Opening (ISO) ARPA-H -SOL-26-142. For detailed information regarding the ADVOCATE Proposers' Day, review Special Notice (SN) ARPA-H-SN-26-139.